BioWa, Inc. has announced that MedImmune, Inc. has licensed BioWa's POTELLIGENT™ technology for use in researching and developing select MedImmune antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
"We are delighted that MedImmune, a recognized biotechnology leader, has decided to use our POTELLIGENT™ technology as a method for maximizing the potential of therapeutic antibodies," said Dr. Nobuo Hanai, BioWa President and CEO.
"We believe that this collaboration with MedImmune highlights the potential advantages of our ADCC-enhancing technology and furthers BioWa's goal to bring about safe and more effective treatments for cancer and other life-threatening and debilitating diseases."
Under the terms of the agreement, BioWa will provide MedImmune with non- exclusive commercial rights to use the technology to enhance ADCC in developing antibodies for multiple targets.
In return, BioWa will receive technology access fees, and may receive milestone payments and royalties on products developed by MedImmune.